Abstract 5P
Background
Tertiary Lymphoid Structures (TLS) mediate local antitumor immunity. Since cancer immunotherapy, TLS interests grown considerably. We examined TLS and tumor stromal blood vessels for BC molecular subtypes associated with recurrence, lymphovascu-lar (LIV), and perineural invasion (PnI).
Methods
CD34/SMA double immunostaining revealed TLS high endothelial venules and BC tumor stromal immature and mature blood vessels. Statistical study linked microscopic data to recurrence, LIV, and PnI.
Results
TLS- subgroups have higher LIV, PnI, and recurrence (p<0.001), except for Luminal A type. LIV and PnI rise in HER2+/TLS- subgroups (p<0.001). TNBC/TLS- had the highest recurrence and invasion risks. TNBC/TLS- subgroup recurrence is related to tumor grade and LIV/PnI (p<0.001), unlike other TLS- subgroups. PnI but not LVI are related with TNBC/TLS+ subgroup recurrence (p<0.001).
Conclusions
TLS affect BC molecular subtype recurrence, LVI, and PnI differently. Its antitumor immunity mediator seems closely associated to tumor aggressiveness and stromal blood vessels.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
46P - Effect of coadministration of antioxidant chlorophyllin with docetaxel on invasion and metastasis in triple-negative breast cancer in vivo/in vitro
Presenter: Ayse Burus
Session: Poster session 09
47P - An ozone delivery system by cisplatin prodrug self-assembling micelles combining microwave to sensitizing immune checkpoint inhibitor in triple-negative breast cancer
Presenter: Dan Zheng
Session: Poster session 09
48P - Non-steroid anti-inflammatory treatment enhances the efficacy of modulated electro hyperthermia on triple-negative breast cancer and melanoma cancer models in vivo
Presenter: Nino Giunashvili
Session: Poster session 09
49P - Circulating miRNA signatures to predict recurrence in patients with pathological complete response of triple-negative breast cancer
Presenter: Ana Julia de Freitas
Session: Poster session 09
50P - Application and mechanism of tarloxotinib in HER2-positive breast cancer
Presenter: Xinyi Shao
Session: Poster session 09
51P - Nanoengineered sonosensitive platelets for synergistically augmented sonodynamic breast tumour therapy by glutamine deprivation and cascading thrombosis
Presenter: Liqiang Zhou
Session: Poster session 09
53P - Treatment of cancer cells based on circulating tumor cell’s expression profile using off-label drugs
Presenter: Panagiotis Apostolou
Session: Poster session 09
54P - Enhanced oxidative phosphorylation of metastasis-initiating cells facilitates esophageal tumor cell seeding in lymph nodes
Presenter: Shanshan Li
Session: Poster session 09
55P - Transcriptional profiles of engineered T cells stimulated with different receptor structures and co-stimulatory domains
Presenter: Ungue Shin
Session: Poster session 09
56P - SLC34A2-ROS1 L2026M+G2032R confers resistance to ROS1 tyrosine kinase inhibitors in Ba/F3 cells through a reduced ATP binding pocket volume
Presenter: Christa Dijkhuizen
Session: Poster session 09